Basics of radiation biology when treating hyperproliferative benign diseases

Frontiers in Immunology

Volumn 8, Issue MAY, 2017, Pages

  Rödel, Franz ^a   Fournier, Claudia ^b   Wiedemann, Julia ^b   Merz, Felicitas ^b   Gaipl, Udo S ^c   Frey, Benjamin ^c   Keilholz, Ludwig ^d   Seegenschmiedt, M Heinrich ^e   Rödel, Claus ^a   Hehlgans, Stephanie ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GSI HELMHOLTZZENTRUM FÜR SCHWERIONENFORSCHUNG GMBH   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d Clinical Center Bayreuth   (Germany)

^e Strahlenzentrum Hamburg MVZ   (Germany)

Author keywords

Anti inflammatory effect; Antiproliferative effect; Cytokines; Fibroblasts myofibroblast; Hyperproliferative diseases; Low dose radiation therapy

Indexed keywords

FREE RADICAL;

ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BENIGN NEOPLASM; BURN; CANCER RISK; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DNA DAMAGE; ENDOTHELIUM CELL; FIBROBLAST; FLOW CYTOMETRY; HOSPITAL ADMISSION; HUMAN; HYPERPROLIFERATIVE BENIGN DISEASE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOPHENOTYPING; INCIDENCE; INFLAMMATION; INJURY; IONIZING RADIATION; IRRADIATION; MACROPHAGE; MICROENVIRONMENT; MYOFIBROBLAST; PROTEIN EXPRESSION; RADIATION EXPOSURE; RADIOBIOLOGY; REVIEW; SCAR FORMATION; SIGNAL TRANSDUCTION;

EID: 85020004749     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00519     Document Type: Review

References (117)

1. Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, et al. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res (2003) 159(3):283-300. doi: 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2
2. Mladenov E, Magin S, Soni A, Iliakis G. DNA double-strand-break repair in higher eukaryotes and its role in genomic instability and cancer: cell cycle and proliferation-dependent regulation. Semin Cancer Biol (2016) 3(7-38):51-64. doi:10.1016/j.semcancer.2016.03.003
3. Roos WP, Thomas AD, Kaina B. DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer (2016) 16(1):20-33. doi:10.1038/nrc.2015.2
4. Seegenschmiedt MH, Makoski HB, Trott KR, Brady LWE. Radiotherapy for Non-Malignant Disorders. Berlin, Heidelberg: Springer Verlag (2008)
5. Seegenschmiedt MH, Micke O, Niewald M, Mucke R, Eich HT, Kriz J, et al. DEGRO guidelines for the radiotherapy of non-malignant disorders: part III: hyperproliferative disorders. Strahlenther Onkol (2015) 191(7):541-8. doi:10.1007/s00066-015-0818-2
6. Ott OJ, Niewald M, Weitmann HD, Jacob I, Adamietz IA, Schaefer U, et al. DEGRO guidelines for the radiotherapy of non-malignant disorders. Part II: painful degenerative skeletal disorders. Strahlenther Onkol (2015) 191(1):1-6. doi:10.1007/s00066-014-0757-3
7. Suit H, Spiro I. Radiation treatment of benign mesenchymal disease. Semin Radiat Oncol (1999) 9(2):171-8. doi:10.1053/SRAO00900171
8. Seegenschmiedt MH, Micke O, Muecke R. Radiotherapy for non-malignant disorders: state of the art and update of the evidence-based practice guidelines. Br J Radiol (2015) 88(1051):20150080. doi:10.1259/bjr.20150080
9. Seegenschmiedt MH, Micke O. [Radiotherapy of non-malignant diseases. Past, present and future]. Strahlenther Onkol (2012) 188(Suppl 3):272-90. doi:10.1007/s00066-012-0195-z
10. Lanting R, Broekstra DC, Werker PM, van den Heuvel ER. A systematic review and meta-analysis on the prevalence of Dupuytren disease in the general population of Western countries. Plast Reconstr Surg (2014) 133(3):593-603. doi:10.1097/01.prs.0000438455.37604.0f
11. Hindocha S, McGrouther DA, Bayat A. Epidemiological evaluation of Dupuytren's disease incidence and prevalence rates in relation to etiology. Hand (N Y) (2009) 4(3):256-69. doi:10.1007/s11552-008-9160-9
12. Ross DC. Epidemiology of Dupuytren's disease. Hand Clin (1999) 15(1):53-62, vi
13. Dolmans GH, Werker PM, Hennies HC, Furniss D, Festen EA, Franke L, et al. Wnt signaling and Dupuytren's disease. N Engl J Med (2011) 365(4):307-17. doi:10.1056/NEJMoa1101029
14. Hu FZ, Nystrom A, Ahmed A, Palmquist M, Dopico R, Mossberg I, et al. Mapping of an autosomal dominant gene for Dupuytren's contracture to chromosome 16q in a Swedish family. Clin Genet (2005) 68(5):424-9. doi:10.1111/j.1399-0004.2005.00504.x
15. Shih B, Bayat A. Scientific understanding and clinical management of Dupuytren disease. Nat Rev Rheumatol (2010) 6(12):715-26. doi:10.1038/nrrheum.2010.180
16. Bovenzi M, Franzinelli A, Scattoni L, Vannuccini L. Hand-arm vibration syndrome among travertine workers: a follow up study. Occup Environ Med (1994) 51(6):361-5. doi:10.1136/oem.51.6.361
17. Godtfredsen NS, Lucht H, Prescott E, Sorensen TI, Gronbaek M. A prospective study linked both alcohol and tobacco to Dupuytren's disease. J Clin Epidemiol (2004) 57(8):858-63. doi:10.1016/j.jclinepi.2003.11.015
18. Heyd R, Dorn AP, Herkstroter M, Rodel C, Muller-Schimpfle M, Fraunholz I. Radiation therapy for early stages of morbus Ledderhose. Strahlenther Onkol (2010) 186(1):24-9. doi:10.1007/s00066-009-2049-x
19. Aviles E, Arlen M, Miller T. Plantar fibromatosis. Surgery (1971) 69(1):117-20
20. Fausto de Souza D, Micaelo L, Cuzzi T, Ramos ESM. Ledderhose disease: an unusual presentation. J Clin Aesthet Dermatol (2010) 3(9):45-7
21. Allen RA, Woolner LB, Ghormley RK. Soft-tissue tumors of the sole; with special reference to plantar fibromatosis. J Bone Joint Surg Am (1955) 37-A(1):14-26. doi:10.2106/00004623-195537010-00002
22. Guix B, Andres A, Salort P. Keloids and hypertrophic scars. In: Seegenschmiedt MH, editor. Radiotherapy for Nonmalignat Disorders. Berlin: Springer (2008) 209-24
23. Alhady SM, Sivanantharajah K. Keloids in various races. A review of 175 cases. Plast Reconstr Surg (1969) 44(6):564-6. doi:10.1097/00006534-196912000-00006
24. Mustoe TA, Cooter RD, Gold MH, Hobbs FD, Ramelet AA, Shakespeare PG, et al. Panel on Scar: international clinical recommendations on scar management. Plast Reconstr Surg (2002) 110(2):560-71. doi:10.1097/00006534-200208000-00031
25. Werker P, Dias J, Eaton C, Reichert B, Wach BE. Dupuytren Disease and Related Diseases - The Cutting Edge. Berlin, Heidelberg: Springer Verlag (2016)
26. Betz N, Ott OJ, Adamietz B, Sauer R, Fietkau R, Keilholz L. Radiotherapy in early-stage Dupuytren's contracture. Long-term results after 13 years. Strahlenther Onkol (2010) 186(2):82-90. doi:10.1007/s00066-010-2063-z
27. Kal HB, Veen RE. Biologically effective doses of postoperative radiotherapy in the prevention of keloids. Dose-effect relationship. Strahlenther Onkol (2005) 181(11):717-23. doi:10.1007/s00066-005-1407-6
28. Kutzner J, Schneider L, Seegenschmiedt MH. [Radiotherapy of keloids. Patterns of care study - results]. Strahlenther Onkol (2003) 179(1):54-8. doi:10.1007/s00066-003-1023-2
29. Arnault JP, Peiffert D, Latarche C, Chassagne JF, Barbaud A, Schmutz JL. Keloids treated with postoperative Iridium 192* brachytherapy: a retrospective study. J Eur Acad Dermatol Venereol (2009) 23(7):807-13. doi:10.1111/j.1468-3083.2009.03190.x
30. Ward JF. DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability. Prog Nucleic Acid Res Mol Biol (1988) 35:95-125. doi:10.1016/S0079-6603(08)60611-X
31. O'Driscoll M, Jeggo PA. The role of double-strand break repair - insights from human genetics. Nat Rev Genet (2006) 7(1):45-54. doi:10.1038/nrg1746
32. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature (2009) 461(7267):1071-8. doi:10.1038/nature08467
33. Rodel F, Frey B, MulthoffG, Gaipl U. Contribution of the immune system to bystander and non-targeted effects of ionizing radiation. Cancer Lett (2015) 356(1):105-13. doi:10.1016/j.canlet.2013.09.015
34. Brown WM, Doll R. Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis. Br Med J (1965) 2(5474):1327-32. doi:10.1136/bmj.2.5474.1327
35. Mazonakis M, Damilakis J. Cancer risk after radiotherapy for benign diseases. Phys Med (2017). doi:10.1016/j.ejmp.2017.01.014
36. McKeown SR, Hatfield P, Prestwich RJ, Shaffer RE, Taylor RE. Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation. Br J Radiol (2015) 88(1056):20150405. doi:10.1259/bjr.20150405
37. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP (2007) 37(2-4):1-332. doi:10.1016/j.icrp.2007.10.003
38. Trott KR, Kamprad F. Estimation of cancer risks from radiotherapy of benign diseases. Strahlenther Onkol (2006) 182(8):431-6. doi:10.1007/s00066-006-1542-8
39. Rodemann HP, Bamberg M. Cellular basis of radiation-induced fibrosis. Radiother Oncol (1995) 35(2):83-90. doi:10.1016/0167-8140(95)01540-W
40. Grenfell S, Borg M. Radiotherapy in fascial fibromatosis: a case series, literature review and considerations for treatment of early-stage disease. J Med Imaging Radiat Oncol (2014) 58(5):641-7. doi:10.1111/1754-9485.12178
41. Cordova A, Tripoli M, Corradino B, Napoli P, Moschella F. Dupuytren's contracture: an update of biomolecular aspects and therapeutic perspectives. J Hand Surg Br (2005) 30(6):557-62. doi:10.1016/j.jhsb.2005.07.002
42. Fitzgerald AM, Kirkpatrick JJ, Naylor IL. Dupuytren's disease. The way forward? J Hand Surg Br (1999) 24(4):395-9. doi:10.1054/jhsb.1999.0207
43. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol (2002) 3(5):349-63. doi:10.1038/nrm809
44. Mayerl C, Del Frari B, Parson W, Boeck G, Piza-Katzer H, Wick G, et al. Characterisation of the inflammatory response in Dupuytren's disease. J Plast Surg Hand Surg (2016) 50(3):171-9. doi:10.3109/2000656X.2016.1140054
45. Shih B, Brown JJ, Armstrong DJ, Lindau T, Bayat A. Differential gene expression analysis of subcutaneous fat, fascia, and skin overlying a Dupuytren's disease nodule in comparison to control tissue. Hand (N Y) (2009) 4(3):294-301. doi:10.1007/s11552-009-9164-0
46. Qu M, Song N, Chai G, Wu X, Liu W. Pathological niche environment transforms dermal stem cells to keloid stem cells: a hypothesis of keloid formation and development. Med Hypotheses (2013) 81(5):807-12. doi:10.1016/j.mehy.2013.08.033
47. Jiao H, Fan J, Cai J, Pan B, Yan L, Dong P, et al. Analysis of characteristics similar to autoimmune disease in keloid patients. Aesthetic Plast Surg (2015) 39(5):818-25. doi:10.1007/s00266-015-0542-4
48. Do DV, Ong CT, Khoo YT, Carbone A, Lim CP, Wang S, et al. Interleukin-18 system plays an important role in keloid pathogenesis via epithelial-mesenchymal interactions. Br J Dermatol (2012) 166(6):1275-88. doi:10.1111/j.1365-2133.2011.10721.x
49. Zhang M, Xu Y, Liu Y, Cheng Y, Zhao P, Liu H, et al. Chemokine-like factor 1 (CKLF-1) is overexpressed in keloid patients: a potential indicating factor for keloid-predisposed individuals. Medicine (Baltimore) (2016) 95(11):e3082. doi:10.1097/MD.0000000000003082
50. Abraham DJ, Eckes B, Rajkumar V, Krieg T. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep (2007) 9(2):136-43. doi:10.1007/s11926-007-0008-z
51. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol (2007) 170(6):1807-16. doi:10.2353/ajpath.2007.070112
52. Gabbiani G, Ryan GB, Majne G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia (1971) 27(5):549-50. doi:10.1007/BF02147594
53. Rudolph R, Vande Berg J. The myofibroblast in Dupuytren's contracture. Hand Clin (1991) 7(4):683-92
54. Berndt A, Kosmehl H, Katenkamp D, Tauchmann V. Appearance of the myofibroblastic phenotype in Dupuytren's disease is associated with a fibronectin, laminin, collagen type IV and tenascin extracellular matrix. Pathobiology (1994) 62(2):55-8. doi:10.1159/000163879
55. Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep (2006) 8(2):145-50. doi:10.1007/s11926-006-0055-x
56. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med (2007) 13(8):952-61. doi:10.1038/nm1613
57. Willis BC, duBois RM, Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc Am Thorac Soc (2006) 3(4):377-82. doi:10.1513/pats.200601-004TK
58. Piera-Velazquez S, Mendoza FA, Jimenez SA. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of human fibrotic diseases. J Clin Med (2016) 5(4):E45. doi:10.3390/jcm5040045
59. Iqbal SA, Hayton MJ, Watson JS, Szczypa P, Bayat A. First identification of resident and circulating fibrocytes in Dupuytren's disease shown to be inhibited by serum amyloid P and Xiapex. PLoS One (2014) 9(6):e99967. doi:10.1371/journal.pone.0099967
60. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med (1994) 1(1):71-81
61. Bayreuther K, Rodemann HP, Francz PI, Maier K. Differentiation of fibroblast stem cells. J Cell Sci Suppl (1988) 10:115-30. doi:10.1242/jcs.1988.Supplement_10.9
62. Bayreuther K, Rodemann HP, Hommel R, Dittmann K, Albiez M, Francz PI. Human skin fibroblasts in vitro differentiate along a terminal cell lineage. Proc Natl Acad Sci U S A (1988) 85(14):5112-6. doi:10.1073/pnas.85.14.5112
63. Rodemann HP, Peterson HP, Schwenke K, von Wangenheim KH. Terminal differentiation of human fibroblasts is induced by radiation. Scanning Microsc (1991) 5(4):1135-42
64. Bumann J, Santo-Holtje L, Loffler H, Bamberg M, Rodemann HP. Radiation-induced alterations of the proliferation dynamics of human skin fibroblasts after repeated irradiation in the subtherapeutic dose range. Strahlenther Onkol (1995) 171(1):35-41
65. Fournier C, Scholz M, Weyrather WK, Rodemann HP, Kraft G. Changes of fibrosis-related parameters after high-and low-LET irradiation of fibroblasts. Int J Radiat Biol (2001) 77(6):713-22. doi:10.1080/095530000110045025
66. Bayreuther K, Francz PI, Rodemann HP. Fibroblasts in normal and pathological terminal differentiation, aging, apoptosis and transformation. Arch Gerontol Geriatr (1992) 15(Suppl 1):47-74. doi:10.1016/S0167-4943(05)80006-8
67. Herskind C, Rodemann HP. Spontaneous and radiation-induced differentiation of fibroblasts. Exp Gerontol (2000) 35(6-7):747-55. doi:10.1016/S0531-5565(00)00168-6
68. Fournier C, Winter M, Zahnreich S, Nasonova E, Melnikova L, Ritter S. Interrelation amongst differentiation, senescence and genetic instability in long-term cultures of fibroblasts exposed to different radiation qualities. Radiother Oncol (2007) 83(3):277-82. doi:10.1016/j.radonc.2007.04.022
69. Fournier C, Wiese C, Taucher-Scholz G. Accumulation of the cell cycle regulators TP53 and CDKN1A (p21) in human fibroblasts after exposure to low-and high-LET radiation. Radiat Res (2004) 161(6):675-84. doi:10.1667/RR3182
70. Bluwstein A, Kumar N, Leger K, Traenkle J, Oostrum J, Rehrauer H, et al. PKC signaling prevents irradiation-induced apoptosis of primary human fibroblasts. Cell Death Dis (2013) 4:e498. doi:10.1038/cddis.2013.15
71. Ji J, Tian Y, Zhu YQ, Zhang LY, Ji SJ, Huan J, et al. Ionizing irradiation inhibits keloid fibroblast cell proliferation and induces premature cellular senescence. J Dermatol (2015) 42(1):56-63. doi:10.1111/1346-8138.12702
72. Passos JF, Nelson G, Wang C, Richter T, Simillion C, Proctor CJ, et al. Feedback between p21 and reactive oxygen production is necessary for cell senescence. Mol Syst Biol (2010) 6:347. doi:10.1038/msb.2010.5
73. Kollarovic G, Studencka M, Ivanova L, Lauenstein C, Heinze K, Lapytsko A, et al. To senesce or not to senesce: how primary human fibroblasts decide their cell fate after DNA damage. Aging (Albany NY) (2016) 8(1):158-77. doi:10.18632/aging.100883
74. Travis EL. Organizational response of normal tissues to irradiation. Semin Radiat Oncol (2001) 11(3):184-96. doi:10.1053/srao.2001.25243
75. Richards SA, Muter J, Ritchie P, Lattanzi G, Hutchison CJ. The accumulation of un-repairable DNA damage in laminopathy progeria fibroblasts is caused by ROS generation and is prevented by treatment with N-acetyl cysteine. Hum Mol Genet (2011) 20(20):3997-4004. doi:10.1093/hmg/ddr327
76. Dettmering T, Zahnreich S, Colindres-Rojas M, Durante M, Taucher-Scholz G, Fournier C. Increased effectiveness of carbon ions in the production of reactive oxygen species in normal human fibroblasts. J Radiat Res (2015) 56(1):67-76. doi:10.1093/jrr/rru083
77. Nathan C, Cunningham-Bussel A. Beyond oxidative stress: an immunologist's guide to reactive oxygen species. Nat Rev Immunol (2013) 13(5):349-61. doi:10.1038/nri3423
78. Robbins ME, Zhao W. Chronic oxidative stress and radiation-induced late normal tissue injury: a review. Int J Radiat Biol (2004) 80(4):251-9. doi:10.1080/09553000410001692726
79. Zhao W, Robbins ME. Inflammation and chronic oxidative stress in radiation-induced late normal tissue injury: therapeutic implications. Curr Med Chem (2009) 16(2):130-43. doi:10.2174/092986709787002790
80. Murrell GA, Francis MJ, Bromley L. Free radicals and Dupuytren's contracture. Br Med J (Clin Res Ed) (1987) 295(6610):1373-5. doi:10.1136/bmj.295.6610.1373
81. Murrell GA, Francis MJ, Bromley L. Modulation of fibroblast proliferation by oxygen free radicals. Biochem J (1990) 265(3):659-65. doi:10.1042/bj2650659
82. Baird KS, Crossan JF, Ralston SH. Abnormal growth factor and cytokine expression in Dupuytren's contracture. J Clin Pathol (1993) 46(5):425-8. doi:10.1136/jcp.46.5.425
83. Bianchi E, Taurone S, Bardella L, Signore A, Pompili E, Sessa V, et al. Involvement of pro-inflammatory cytokines and growth factors in the pathogenesis of Dupuytren's contracture: a novel target for a possible future therapeutic strategy? Clin Sci (Lond) (2015) 129(8):711-20. doi:10.1042/CS20150088
84. Kloen P, Jennings CL, Gebhardt MC, Springfield DS, Mankin HJ. Transforming growth factor-beta: possible roles in Dupuytren's contracture. J Hand Surg Am (1995) 20(1):101-8. doi:10.1016/S0363-5023(05)80067-X
85. Alman BA, Naber SP, Terek RM, Jiranek WA, Goldberg MJ, Wolfe HJ. Platelet-derived growth factor in fibrous musculoskeletal disorders: a study of pathologic tissue sections and in vitro primary cell cultures. J Orthop Res (1995) 13(1):67-77. doi:10.1002/jor.1100130111
86. Badalamente MA, Sampson SP, Hurst LC, Dowd A, Miyasaka K. The role of transforming growth factor beta in Dupuytren's disease. J Hand Surg Am (1996) 21(2):210-5. doi:10.1016/S0363-5023(96)80102-X
87. Verjee LS, Verhoekx JS, Chan JK, Krausgruber T, Nicolaidou V, Izadi D, et al. Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target. Proc Natl Acad Sci U S A (2013) 110(10):E928-37. doi:10.1073/pnas.1301100110
88. Krause C, Kloen P, Ten Dijke P. Elevated transforming growth factor beta and mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytren's disease fibroblasts. Fibrogenesis Tissue Repair (2011) 4(1):14. doi:10.1186/1755-1536-4-14
89. Alioto RJ, Rosier RN, Burton RI, Puzas JE. Comparative effects of growth factors on fibroblasts of Dupuytren's tissue and normal palmar fascia. J Hand Surg Am (1994) 19(3):442-52. doi:10.1016/0363-5023(94)90059-0
90. Schmierer B, Hill CS. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol (2007) 8(12):970-82. doi:10.1038/nrm2297
91. Kloen P. New insights in the development of Dupuytren's contracture: a review. Br J Plast Surg (1999) 52(8):629-35. doi:10.1054/bjps.1999.3187
92. Wong M, Mudera V. Feedback inhibition of high TGF-beta1 concentrations on myofibroblast induction and contraction by Dupuytren's fibroblasts. J Hand Surg Br (2006) 31(5):473-83. doi:10.1016/j.jhsb.2006.05.007
93. Sullivan DE, Ferris M, Pociask D, Brody AR. Tumor necrosis factor-alpha induces transforming growth factor-beta1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am J Respir Cell Mol Biol (2005) 32(4):342-9. doi:10.1165/rcmb.2004-0288OC
94. Zhu Z, Ding J, Tredget EE. The molecular basis of hypertrophic scars. Burns Trauma (2016) 4:2. doi:10.1186/s41038-015-0026-426
95. Andrew JG, Andrew SM, Ash A, Turner B. An investigation into the role of inflammatory cells in Dupuytren's disease. J Hand Surg Br (1991) 16(3):267-71. doi:10.1016/0266-7681(91)90051-O
96. Baird KS, Alwan WH, Crossan JF, Wojciak B. T-cell-mediated response in Dupuytren's disease. Lancet (1993) 341(8861):1622-3. doi:10.1016/0140-6736(93)90760-E
97. Conrad S, Ritter S, Fournier C, NixdorffK. Differential effects of irradiation with carbon ions and X-rays on macrophage function. J Radiat Res (2009) 50(3):223-31. doi:10.1269/jrr.08115
98. Tsukimoto M, Homma T, Mutou Y, Kojima S. 0.5 Gy gamma radiation suppresses production of TNF-alpha through up-regulation of MKP-1 in mouse macrophage RAW264.7 cells. Radiat Res (2009) 171(2):219-24. doi:10.1667/RR1351.1
99. Lodermann B, Wunderlich R, Frey S, Schorn C, Stangl S, Rodel F, et al. Low dose ionising radiation leads to a NF-kappaB dependent decreased secretion of active IL-1beta by activated macrophages with a discontinuous dose-dependency. Int J Radiat Biol (2012) 88(10):727-34. doi:10.3109/09553002.2012.689464
100. Wunderlich R, Ernst A, Rodel F, Fietkau R, Ott O, Lauber K, et al. Low and moderate doses of ionizing radiation up to 2 Gy modulate transmigration and chemotaxis of activated macrophages, provoke an anti-inflammatory cytokine milieu, but do not impact upon viability and phagocytic function. Clin Exp Immunol (2015) 179(1):50-61. doi:10.1111/cei.12344
101. Hildebrandt G, Loppnow G, Jahns J, Hindemith M, Anderegg U, Saalbach A, et al. Inhibition of the iNOS pathway in inflammatory macrophages by low-dose X-irradiation in vitro. Is there a time dependence? Strahlenther Onkol (2003) 179(3):158-66. doi:10.1007/s00066-003-1044-x
102. Schaue D, Marples B, Trott KR. The effects of low-dose X-irradiation on the oxidative burst in stimulated macrophages. Int J Radiat Biol (2002) 78(7):567-76. doi:10.1080/09553000210126457
103. Meek RM, McLellan S, Crossan JF. Dupuytren's disease. A model for the mechanism of fibrosis and its modulation by steroids. J Bone Joint Surg Br (1999) 81(4):732-8. doi:10.1302/0301-620X.81B4.9163
104. Meek RM, McLellan S, Reilly J, Crossan JF. The effect of steroids on Dupuytren's disease: role of programmed cell death. J Hand Surg Br (2002) 27(3):270-3. doi:10.1054/jhsb.2001.0742
105. Speyer CL, Ward PA. Role of endothelial chemokines and their receptors during inflammation. J Invest Surg (2011) 24(1):18-27. doi:10.3109/08941939.2010.521232
106. Roedel F, Kley N, Beuscher HU, Hildebrandt G, Keilholz L, Kern P, et al. Anti-inflammatory effect of low-dose X-irradiation and the involvement of a TGF-beta1-induced down-regulation of leukocyte/endothelial cell adhesion. Int J Radiat Biol (2002) 78(8):711-9. doi:10.1080/09553000210137671
107. Rödel F, Schaller U, Schultze-Mosgau S, Beuscher HU, Keilholz L, Herrmann M, et al. The induction of TGF-beta(1) and NF-kappaB parallels a biphasic time course of leukocyte/endothelial cell adhesion following low-dose X-irradiation. Strahlenther Onkol (2004) 180(4):194-200. doi:10.1007/s00066-004-1237-y
108. Kern PM, Keilholz L, Forster C, Hallmann R, Herrmann M, Seegenschmiedt MH. Low-dose radiotherapy selectively reduces adhesion of peripheral blood mononuclear cells to endothelium in vitro. Radiother Oncol (2000) 54(3):273-82. doi:10.1016/S0167-8140(00)00141-9
109. Hildebrandt G, Radlingmayr A, Rosenthal S, Rothe R, Jahns J, Hindemith M, et al. Low-dose radiotherapy (LD-RT) and the modulation of iNOS expression in adjuvant-induced arthritis in rats. Int J Radiat Biol (2003) 79(12):993-1001. doi:10.1080/09553000310001636639
110. Rehman S, Goodacre R, Day PJ, Bayat A, WesterhoffHV. Dupuytren's: a systems biology disease. Arthritis Res Ther (2011) 13(5):238. doi:10.1186/ar3438
111. Rubin P, Soni A, Williams JP. The molecular and cellular biologic basis for the radiation treatment of benign proliferative diseases. Semin Radiat Oncol (1999) 9(2):203-14. doi:10.1053/SRAO00900203
112. Yarnold J, Brotons MC. Pathogenetic mechanisms in radiation fibrosis. Radiother Oncol (2010) 97(1):149-61. doi:10.1016/j.radonc.2010.09.002
113. Rödel F, Frey B, Manda K, Hildebrandt G, Hehlgans S, Keilholz L, et al. Immunomodulatory properties and molecular effects in inflammatory diseases of low-dose X-irradiation. Front Oncol (2012) 2:120. doi:10.3389/fonc.2012.00120
114. Ott OJ, Hertel S, Gaipl US, Frey B, Schmidt M, Fietkau R. The Erlangen dose optimization trial for low-dose radiotherapy of benign painful elbow syndrome. Long-term results. Strahlenther Onkol (2014) 190(3):293-7. doi:10.1007/s00066-013-0504-1
115. Ott OJ, Hertel S, Gaipl US, Frey B, Schmidt M, Fietkau R. The Erlangen dose optimization trial for radiotherapy of benign painful shoulder syndrome. Long-term results. Strahlenther Onkol (2014) 190(4):394-8. doi:10.1007/s00066-013-0520-1
116. Rühle PF, Fietkau R, Gaipl US, Frey B. Development of a modular assay for detailed immunophenotyping of peripheral human whole blood samples by multicolor flow cytometry. Int J Mol Sci (2016) 17(8):E1316. doi:10.3390/ijms17081316
117. Rühle PF, Wunderlich R, Deloch L, Fournier C, Maier A, Klein G, et al. Modulation of the peripheral immune system after low-dose radon spa therapy: detailed longitudinal immune monitoring of patients within the RAD-ON01 study. Autoimmunity (2017) 50(2):133-40. doi:10.1080/08916934.2017.1284819